Lipid abnormalities and renal disease: Is dyslipidemia a predictor of progression of renal disease?

American Journal of the Medical Sciences

Volumn 325, Issue 6, 2003, Pages 340-348

  Crook, Errol D ^a,b   Thallapureddy, Anantha ^a   Migdal, Stephen ^a   Flack, John M ^a,b   Greene, Eddie L ^d   Salahudeen, Abdullah ^c   Tucker, John K ^e   Taylor Jr , Herman A ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chronic kidney disease; Dyslipidemia; HDL cholesterol; Jackson Heart Study; LDL cholesterol; Triglycerides

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; ENDOTHELIUM INJURY; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MACROPHAGE ACTIVATION; NEGRO; PROTEINURIA;

EID: 0038517698     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200306000-00005     Document Type: Conference Paper

References (70)

1. Kannel WB, Castelli WP, Gordon T. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971;74:1-12.
2. Assmann G, Schulte H. The Prospective Cardiovascular Munster Study (PROCAM): prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary artery disease. Am Heart J 1988;1116:1713-24.
3. Attman PO, Samuelsson O, Allopovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:373-92.
4. Samuelsson O, Attman PO, Knight-Gibson C, et al. Lipoprotein abnormalities without hyperlipidemia in moderate renal insufficiency. Nephrol Dial Transplant 1994;9:1580-5.
5. Ma KW, Greene EI, Rai JL. Cardiovascular risk factors in chronic renal failure and hemodialysis population. Am J Kidney Dis 1992;19:505-13.
6. Crook ED, Flack JM, Salem M, et al. Primary renal disease as a cardiovascular disease risk factor. Am J Med Sci 2002;324:138-45.
7. Klag M, Whelton P, Randall B, et al. Blood pressure and endstage renal disease in men. N Engl J Med 1996;334:13-8.
8. Stenvinkel P, Alvestrano A, Bergstrom J, et al. Factors influencing progression in patients with chronic renal failure. J Intern Med 1989;226:183-8.
9. Keane WF. The role of lipids in renal disease: Future challenges. Kidney Int 2000;Suppl 75:S27-S31.
10. Samuelsson O, Attman PO, Knight-Gibson C, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998;9:1482-8.
11. Al-Shebeb T, Frohlich J, Magil AB. Glomerular disease in hypercholesterolemic guinea pigs: a pathogenic study. Kidney Int 1988;33:498-50.
12. Diamond JR, Karnovsky MJ. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 1987;32:671-7.
13. Joles JA, Kunter U, Janssen U, et al. Early mechanisms of renal injury in hypercholesterolemic and hyper-triglyceridemic rats. J Am Soc Nephrol 2000;11:669-83.
14. Song K, Shiota N, Takai S, et al. Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys. Atherosclerosis 1998;138:171-82.
15. Lavaud S, Michael O, Sassy-Prigent C, et al. Early influx of glomerular of macrophages precedes glomerulosclerosis in obese Zucker rat model. J Am Soc Nephrol 1996;7:2604-15.
16. Pawluczyk IZ, Harris KP. Cholesterol feeding activates macrophages to upregulate rat mesangial cell fibronectin production. Nephrol Dial Transplant 2000;15:161-6.
17. Kamanna VS, Ramo P, Hanjoo HA, et al. Oxidized low density lipoproteins stimulate monocyte adhesion to glomerular endothelial cells. Kidney Int 1999;55:2192-202.
18. Galle J, Heimloth A, Schwedler S, et al. Effect of HDL and atherogenic lipoproteins on formation of free oxygen radicals and renin release in juxtaglomerular cells. Kidney Int 1997;51:253-60.
19. Kramer-Guth A, Grieber S, Pavenstadt H, et al. Interaction of native and oxidized lipoprotein with human mesangial cells and matrix. Kidney Int 1996 49:1250-67.
20. Nolasco F, Cameron JS, Reuben R, et al. Interstitial foam cells in the nephrotic syndrome belong to the monocyte/macrophage lineage. Proc Eur Dial Transplant Assoc 1984;21:666-71.
21. Ha H, Roh DD, Kirschenbauss MA, et al. Atherogenic lipoproteins enhances mesangial cell expression of platelet derived growth factor; role of protein tyrosine kinase and cyclic AMP dependent protein kinase A. J Lab Clin Med 1998;131:456-65.
22. Mugge A, Brandes RP, Bogus RH, et al. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994;24:994-98.
23. Hansen PR, Kharazmic AK, Jauhianen M, et al. Induction of free radical generation in human monocytes by lipoprotein (a). Eur J Clin Invest 1994;24:497-9.
24. Nishidha Y, Oda H, Yarioma N, et al. Effect of lipoproteins on mesangial cell proliferation. Kidney Int 1999;71:S51-3.
25. Keane WF, Massy ZA, Kim Y, et al. LDL induced expression of IL-6, a marker of human mesangial cell inflammation. Effects of oxidation and modulation by statins. Biochem Biophys Res Commun 2000;267:536-40.
26. Harris KPG, Lefkowith JB, Klahr S, et al. Essential fatty acid deficiency ameliorates acute renal dysfunction in the rat after administration of the aminonucleoside of puromycin. J Clin Invest 1990;86:1115-23.
27. Humes HD, Nguyen VD, Cieslinski DA, et al. The role of free fatty acids in hypoxia-induced injury to renal proximal tubule cells. Am J Physiol 1989;258:F688-96.
28. Thomas ME, Schreiner GF. The contribution of proteinuria to progressive renal injury: the consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 2001;13:385-98.
29. Ghiggeri GM, Ginevri F, Candiano G, et al. Characterization of cationic albumin in minimal change nephropathy. Kidney Int 1987;32:547-53.
30. Egan BM, Greene EL, Goodfriend TL. Nonesterified fatty acids (NEFAs) in blood pressure control and cardiovascular complications. Curr Hypertens Rep 2001;3:107-16.
31. Greene EL, Lu G, Zhang D, et al. Signaling events mediating the additive effects of oleic acid and angiotensin II on vascular smooth muscle cell migration. Hypertension 2001;37:308-12.
32. Arici M, Brown J, Williams M, et al. Fatty acids carried on albumin modulate proximal tubular cell fibronectin production: a role for protein kinase C. Nephrol Dial Transplant 2002;17:1751-7.
33. Thomas ME, Harris KP, Walls J, et al. Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria. Am J Physiol 2002;283:F640-7.
34. Thomas ME, Morrison AR, Schreiner GF. Metabolic effects of fatty acids bearing albumin on a proximal tubule cell line. Am J Physiol 1995;268:F1177-84.
35. Kees-Folts D, Sadow JL, Schreiner GF. Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 1994;45:1697-709.
36. Takemura T, Yashioka K, Aya N, et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney disease. Kidney Int 1993;43:918-27.
37. Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 1936;12:83-98.
38. Shimamura T. Relationship of dietary intake to the development of glomerulosclerosis in obese Zucker rats. Exp Mol Pathol 1982;36:423-34.
39. Barcelli UO, Weiss M, Beach D, et al. High linoleic acid diets ameliorate diabetic nephropathy in rats. Am J Kidney Dis 1990;16:244-51.
40. Sun L, Halaihel N, Zhang W, et al. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 2002;277:18919-27.
41. Manttari M, Tiula E, Alikoski T, et al. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995;26:670-5.
42. Muntner P, Coresh J, Smith C, et al. Plasma lipids and risk of development of renal dysfunction: The Atherosclerosis Risk in Communities Study. Kidney Int 2000;58:293-301.
43. Lawrence G, Hunsicker, Adler S, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997;51:1908-19.
44. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human renal insufficiency. Nephrol Dial Transplant 1997;12:1908-15.
45. Massy ZA, Khoa TN, Lacour B, et al. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999, 14:2392-7.
46. Nielsen S, Schmitz A, Rehling A, et al. The clinical course of renal function in NIDDM patients with normo- and microalbuminuria. J Intern Med 1997;241:133-41.
47. Cappelli P, Liberato L, Albertazzi A. Role of dyslipidemia in the progression of chronic renal disease. Ren Fail 1998;20:391-7.
48. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998;158:998-1004.
49. Kasiske BL, O'Donnel MP, Cleory MP, et al. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988;33:667-72.
50. Kasiske BL, O'Donnel MP, Garvis WJ, et al. Pharmacological treatment of hyperlipidemia reduces glomerular injury in 5/6 Nephrectomy rat model of CRF. Circ Res 1988;62:367-74.
51. Harris KPG, Pukerson ML, Yates J, et al. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephritic syndrome. Am J Kidney Dis 1990;50:16-23.
52. McFarlane SI, Maniappa R, Francisco R, et al. Clinical review 145: pleiotropic effects of statins, lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451-8.
53. Park JK, Muller DN, Mervaala DN, et al. Cerivastatin prevents angiotensin-II induced renal injury independent of BP and cholesterol lowering effects. Kidney Int 2000;58:1420-30.
54. Borghi C, Dormi A, Veronesi M, et al. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens 2002;4:277-85.
55. Aviram M, Danker G, Cogan O, et al. Lovastatin inhibits LDL oxidation and alters its fluidity and uptake by macrophages, in vitro and in vivo studies. Metabolism 1992;41:229-35.
56. Goppelt-Struete M, Hahn A, Iwanciw D, et al. Regulation of connective tissue growth factor gene expression in human mesangial cells by HMG-CoA reductase inhibitors. Mol Pathol 2001;54:176-9.
57. Yoshimura A, Inui K, Nemoto T, et al. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 1998;9:2027-39.
58. Grandaliano G, Biswas P, Choudhury GG, et al. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Internat 1993;44:503-8.
59. Liao K. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285-8.
60. Furburg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-7.
61. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;21:297-304.
62. Tonelli M, Moye L, Sacks F, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003;138:98-104.
63. Fried L, Orchard T, Kasiske B. Effect of lipid reduction on the progression of renal disease; a meta-analysis. Kidney Int 2001;59:260-9.
64. Sasaki T, Kurata H, Nomruak, et al. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med 1990;29:156-63.
65. Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980-7.
66. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002;324:127-37.
67. Dubbert PM, Carithers T, Sumner AE, et al. Obesity, physical inactivity, and risk for cardiovascular disease. Am J Med Sci 2002;324:116-26.
68. Hovind P, Rossing P, Tarnow L, et al. Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 2001;24:1972-7.
69. Samuelsson O, Attman PO, Knight-Gibson, et al. Plasma levels of lipoprotein (a) do not predict progression of human chronic renal failure. Nephrol Dial Transplant 1996;11:2237-43.
70. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to endstage renal failure. Nephrol Dial Transplant 1996;11:461-7.